![]() ![]() By taking warfarin later in the day, healthcare providers have the opportunity to individualize the dose based on a patient's current international normalized ratio (INR). Patients can take the drug at any time of day, but dosing recommendations are usually for the afternoon or evening. Warfarin is an oral medication administered once daily. However, this mechanism is less clinically significant than enzyme inhibition. Medications with a higher protein binding affinity than warfarin can displace warfarin creating more free warfarin within the bloodstream. ![]() Since the S-enantiomer is more potent and primarily metabolized by CYP 2C9, drug-drug interactions affecting this pathway may be more significant. It is a racemic mixture, with the S-enantiomer being 2.7 to 3.8 times more potent than the R-enantiomer. Warfarin is metabolized via the cytochrome P450 system by CYP 2C9, 1A2, and 3A4. Warfarin's hepatic metabolism and protein binding are the most common mechanisms for the occurrence of drug-drug interactions. These actions render clotting factors inactive and unable to participate in the clotting cascade. Warfarin interferes with the activation of clotting factors by blocking the vitamin K oxidation-reduction cycle needed for the carboxylation of clotting factors, which ultimately lessens the amount of active vitamin K reserves available to act as a cofactor in the formation of glutamic acid residues within the clotting factors mentioned above. This activity occurs through effects on vitamin K-dependent clotting factors (II, VII, IX, and X) and the anticoagulant proteins C and S. Warfarin exhibits its anticoagulation effects via the intrinsic and extrinsic pathways in the clotting cascade. ![]() Warfarin's anticoagulant effects help prevent clot formation and the extension of any current clots, but it has no direct impact on clot removal or reversing ischemic tissue damage.
0 Comments
Leave a Reply. |